logo-loader
Dyadic International Inc

Zacks analyst John Vandermosten bullish on Dyadic International's C1 gene expression platform

Zacks Small Cap Research Senior Biotechnology Analyst John Vandermosten talks to Proactive Investors about his most recent report on Florida-based biotech company Dyadic International Inc (NASDAQ:DYAI).

Vandermosten says Dyadic's most recent collaboration with VTT, a contract research organization, has extended its contract together, to develop its gene expression platform called C1.

Quick facts: Dyadic International Inc

Price: $6.50

Market: NASDAQ
Market Cap: $176.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Dyadic International reveals newest research collaboration

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the biotech saw continued momentum with a research collaboration deal signed with a 'top tier' pharma company.  Emalfarb, who also discussed the firm's second quarter earnings, says this pharma company is aligned...

1 week, 4 days ago

2 min read